Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

January 2, 2018

Conditions
Prostate Cancer
Interventions
DRUG

Goserelin Acetate

The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.

Trial Locations (7)

V2S 3N6

Exdeo Clinical Research Inc., Abbotsford

L4M 7G1

The Male / Female Health and Research Centre, Barrie

L6T 4S5

Jonathan Giddens Medicine Professional Corporation, Brampton

L6H 3P1

The Fe/Male Health Centres, Oakville

M2J 1V1

Stanley Flax Medical Professional Corporation, Toronto

0112

Fridon Todua Research Institute of Clinical Medicine, Tbilisi

0160

MediClubGeorgia, Tbilisi

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Peptigroupe Inc.

INDUSTRY

lead

CMX Research

OTHER

NCT04060043 - Pilot Study to Evaluate the Effects of a Generic Goserelin Acetate in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter